Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
Q3 2024 vs. Q2 2024
How the institutions holding Estrella Immunopharma, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 7 | 1 | 10 | +4 |
| Shares | 123.0K | 7.57K | 200.1K | +84.6K (+73.3%) |
| Value | $129.2K | $7.95K | $232.1K | +$110.9K (+91.4%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Estrella Immunopharma, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 24,963 | $29.0K | 0.00% |
| Vanguard Group Inc | 21,684 | $25.2K | 0.00% |
| Citadel Advisors LLC | 14,531 | $16.9K | 0.00% |
| UBS Group AG | 6,523 | $7.57K | 0.00% |
Sold out (0)
Institutions that held Estrella Immunopharma, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
None.
Not filed for Q3 2024 yet (1)
Institutions that held Estrella Immunopharma, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 7,568 | $7.95K |